Drug intelligence / Profile preview

PM1021

Development stage: Phase 1
Lead developer: BioNTech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PM1021 is a monoclonal antibody that targets T cell immunoglobulin and ITIM domain (TIGIT), an immune checkpoint receptor expressed on various immune cells, particularly tumor-infiltrating lymphocytes. By binding to TIGIT, PM1021 acts as an inhibitor of this pathway, aiming to enhance T cell and natural killer (NK) cell activity against tumors. The drug is being developed primarily for the treatment of advanced malignant solid neoplasms. Its mechanism involves blocking TIGIT-mediated immunosuppression in the tumor microenvironment, thereby stimulating anti-tumor immunity. The developer is Biotheus (a subsidiary of BioNTech), utilizing Adimab's antibody discovery platform. Clinical development has reached Phase 1 trials for advanced solid tumors.

Other names: anti-TIGIT monoclonal antibody PM1021

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on PM1021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM1021.

Explore the full profile